Market Place
Sourcing Support
Larimar Presents Data from Ph 1 & Ph 2 Nomlabofusp at ICAR 2024
18 Nov 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Q3 2024 Finacial Results
30 Oct 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Poster Presentations At ICAR
19 Sep 2024 //
GLOBENEWSWIRE
Larimar Therapeutics to Participate in Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
07 Aug 2024 //
GLOBENEWSWIRE
First rare disease therapies chosen for FDA START programme
05 Jun 2024 //
PHARMAPHORUM
FDA picks Denali, Neurogene and more for rare disease program
04 Jun 2024 //
FIERCE BIOTECH
Larimar In FDA START Pilot For Nomlabofusp In Friedreich`s Ataxia
30 May 2024 //
GLOBENEWSWIRE
Larimar`s Friedreich`s ataxia program free at last from FDA hold
21 May 2024 //
FIERCE BIOTECH
Larimar: FDA Removes Partial Hold On Nomlabofusp Friedreich`s Program
20 May 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
09 May 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Larimar Announces the Dosing of the First Patient in Study for Nomlabofusp
11 Mar 2024 //
GLOBENEWSWIRE
Larimar to Present at the Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
Larimar Announces Closing of Underwritten Public Offering of Common Stock
16 Feb 2024 //
GLOBENEWSWIRE
Larimar Announces Pricing of Underwritten Public Offering of Common Stock
14 Feb 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Proposed Underwritten Public Offering
13 Feb 2024 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Larimar to Present at the Guggenheim 5th Annual Inflammation Conference
01 Nov 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
03 Oct 2023 //
GLOBENEWSWIRE
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
31 Aug 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial
25 Jul 2023 //
ENDPTS
Larimar Receives FDA Clearance to Proceed to Phase 2 Friedreich`s Ataxia Trial
25 Jul 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
17 Jul 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Set to Join Russell 3000 Index
21 Jun 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial
15 May 2023 //
GLOBENEWSWIRE
Larimar reports results from Friedreich’s ataxia drug trial
15 May 2023 //
CLINICAL TRIALS ARENA
Larimar to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
28 Mar 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
07 Feb 2023 //
GLOBENEWSWIRE
Larimar to Present at the 34th Annual Piper Sandler Healthcare Conference
21 Nov 2022 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Issuance of U.S. Patent
20 Oct 2022 //
GLOBENEWSWIRE
Larimar Announces Presentations at International Congress for Ataxia Research
19 Oct 2022 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Closing of Underwritten Offering & Full Exercise
16 Sep 2022 //
GLOBENEWSWIRE
Larimar`s limbo finally ends as FDA removes clinical hold
15 Sep 2022 //
FIERCEBIOTECH
Larimar Therapeutics Announces $70 Million Underwritten Offering
14 Sep 2022 //
GLOBENEWSWIRE
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following
11 Aug 2022 //
GLOBENEWSWIRE
Larimar Tx Announces Presentation at the Upcoming Gordon Research Conference
28 Jul 2022 //
GLOBENEWSWIRE
Larimar Announces Oral Presentation at the Upcoming Gordon Research Conference
28 Jun 2022 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
02 Jun 2022 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Upcoming Poster Presentations
19 May 2022 //
GLOBENEWSWIRE
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
12 May 2022 //
GLOBENEWSWIRE
Larimar in limbo as FDA maintains clinical hold
16 Feb 2022 //
ENDPTS
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
14 Feb 2022 //
GLOBENEWSWIRE
Larimar Therapeutics to Participate in the Piper Sandler 33rd AHC
22 Nov 2021 //
GLOBENEWSWIRE
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
12 Nov 2021 //
GLOBENEWSWIRE
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series
16 Sep 2021 //
GLOBENEWSWIRE
Larimar Therapeutics to Present at the William Blair Biotech Conference 2021
08 Jul 2021 //
GLOBENEWSWIRE
Worldwide Clinical Trials pens Trialbee study matchmaking pact
26 May 2021 //
FIERCEBIOTECH
Larimar Therapeutics slapped with FDA clinical hold
25 May 2021 //
FIERCEBIOTECH
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination
25 May 2021 //
GLOBENEWSWIRE
Larimar Receives EMA Priority Medicines Designation for CTI-1601
20 May 2021 //
GLOBENEWSWIRE
Larimar Reports Positive Topline Phase 1 Clinical Trial Data Showing
11 May 2021 //
GLOBENEWSWIRE
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
10 May 2021 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose
08 Dec 2020 //
GLOBENEWSWIRE
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation
27 Jul 2020 //
GLOBENEWSWIRE
Larimar Announces Dosing of Patients in Third Cohort of Ph1 SAD Trial CTI-1601
20 Jul 2020 //
GLOBENEWSWIRE
